Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy.

Abstract

T cells engineered to express transgenes such as chimeric antigen receptors (CAR) or modified T cell receptors (TCR) represent a new pillar of cancer therapy. Use of CRISPR/Cas gene-editing tools now allows even stronger and more precise control over the fate and function of engineered T cell therapies, including multiplex genome editing to facilitate use of off-the-shelf allogeneic T cells and novel approaches which have the potential to overcome some of the limitations of canonical Cas9-mediated DNA cleavage. This review summarizes the CRISPR/Cas techniques that have been used in preclinical research and outlines those that currently being tested in clinical trials.

• Authors: Nils Wellhausen, Sangya Agarwal, Philipp C Rommel, Saar I Gill, Carl H June
• Journal: Current opinion in immunology (Curr Opin Immunol) Vol. 74 Pg. 76-84 (02 2022) ISSN: 1879-0372 [Electronic] England
• PMID: 34798542 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: Copyright © 2021 Elsevier Ltd. All rights reserved.

Topics

• CRISPR-Cas Systems (genetics)
• Gene Editing (methods)
• Humans
• Immunotherapy
• Immunotherapy, Adoptive (methods)
• Neoplasms (genetics, therapy)
• T-Lymphocytes